Martin S. Maron

Active 1994–2025

Also published as
Martin S Maron
186
Papers
34,941
Citations
90
h-index
178
i10-index

Citations

Citations per year for Martin S. Maron1982: 4 citations1988: 1 citations1991: 1 citations1995: 1 citations1996: 2 citations1997: 2 citations1999: 1 citations2001: 1 citations2003: 13 citations2004: 22 citations2005: 24 citations2006: 41 citations2007: 68 citations2008: 72 citations2009: 123 citations2010: 142 citations2011: 211 citations2012: 200 citations2013: 151 citations2014: 311 citations2015: 259 citations2016: 259 citations2017: 225 citations2018: 254 citations2019: 753 citations2020: 948 citations2021: 1,120 citations2022: 956 citations2023: 744 citations2024: 1,593 citations2025: 642 citations2026: 22 citations1983–1987: no citations, so these years are not shown1989–1990: no citations, so these years are not shown1992–1994: no citations, so these years are not shown1998: no citations, so this year is not shown2000: no citations, so this year is not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,935 citing papers, 24.6% of this breakdownUnited Kingdom: 734 citing papers, 9.3% of this breakdownItaly: 725 citing papers, 9.2% of this breakdownChina: 451 citing papers, 5.7% of this breakdownGermany: 426 citing papers, 5.4% of this breakdownNetherlands: 336 citing papers, 4.3% of this breakdownCanada: 302 citing papers, 3.9% of this breakdownAustralia: 257 citing papers, 3.3% of this breakdownSpain: 228 citing papers, 2.9% of this breakdownFrance: 207 citing papers, 2.6% of this breakdownJapan: 176 citing papers, 2.2% of this breakdownSwitzerland: 153 citing papers, 2% of this breakdown
0%24.6%Other 24.6%

Fields

  • Medicine90.6%
  • Biochemistry, Genetics and Molecular Biology6.7%
  • Engineering0.8%
  • Computer Science0.4%
  • Immunology and Microbiology0.4%
  • Neuroscience0.2%
  • Other0.9%

Topics

  • Cardiomyopathy and Myosin Studies17.2%
  • Cardiovascular Function and Risk Factors10.5%
  • Cardiovascular Effects of Exercise8.2%
  • Cardiac Imaging and Diagnostics6%
  • Cardiac electrophysiology and arrhythmias4.3%
  • Cardiac pacing and defibrillation studies2.9%
  • Other50.9%

Coauthors

All papers

Open in search
  1. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary

    Authors: , , , , , , , , , , , , , , , , , , - Circulation 2020 cited by 997

  2. New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy

    Authors: , , , - Journal of the American College of Cardiology 2015 cited by 1,402

  3. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , - Journal of the American College of Cardiology 2022 cited by 587

  4. Hypertrophic cardiomyopathy

    Authors: , - The Lancet 2012 cited by 1,231

  5. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , - Circulation 2020 cited by 682

  6. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lisa Meng, Amy Wohltman, Theodore P. Abraham - New England Journal of Medicine 2024 cited by 282

  7. Management of Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , - Journal of the American College of Cardiology 2022 cited by 389

  8. Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2014 cited by 1,036

  9. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2023 cited by 193

  10. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lubna Choudhury, Andrew Crean, Dana Dawson, Milind Y. Desai, Eleanor Elstein, Andrew Flett, Matthias G. Friedrich, Stephen B. Heitner, Adam Helms, Daniel Jacoby, Han Kim, Bette Kim, Éric Larose, Masliza Mahmod, Heiko Mahrholdt, Martin S. Maron, Gerry P McCann, Michelle Michels, Saidi Mohiddin, Sherif F. Nagueh, David E. Newby, Iacopo Olivotto, Anjali Owens, François Pierre-Mongeon, Sanjay Prasad, Ornella Rimoldi, Michael Salerno, Jeanette Schulz‐Menger, Mark V. Sherrid, Peter Swoboda, Albert C. van Rossum, Jonathan W. Weinsaft, James A. White, Eric E. Williamson, Rafik Tadros, James S. Ware, Connie R. Bezzina, Martin Farrall, Hugh Watkins - Nature Genetics 2021 cited by 339

  11. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , William Bradlow, Michael Salerno, Stephen B. Heitner, Sanjay Prasad, Saidi Mohiddin, Peter Swoboda, Heiko Mahrholdt, Chiara Bucciarelli‐Ducci, Jonathan W. Weinsaft, Han Kim, Gerry P McCann, Albert C. van Rossum, Eric E. Williamson, Andrew Flett, Dana Dawson, François‐Pierre Mongeon, Iacopo Olivotto, Andrew Crean, Anjali Owens, Lisa Anderson, Elena Biagini, David E. Newby, Colin Berry, Bette Kim, Éric Larose, Theodore P. Abraham, Mark V. Sherrid, Sherif F. Nagueh, Ornella Rimoldi, Eleanor Elstein, Camillo Autore - Journal of the American College of Cardiology 2019 cited by 321

  12. Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction

    Authors: , , , , , , , , , - Circulation 2006 cited by 1,109

  13. Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy

    Authors: , , , , , , , - New England Journal of Medicine 2003 cited by 1,468

  14. Left Ventricular Remodeling in Heart Failure

    Authors: , , , , - JACC. Cardiovascular imaging 2011 cited by 764

  15. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , - Circulation 2017 cited by 268

  16. Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , - Journal of the American College of Cardiology 2005 cited by 809

  17. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm

    Authors: , , , , , , - Journal of the American College of Cardiology 2017 cited by 359

  18. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , - JAMA Cardiology 2019 cited by 317

  19. Hypertrophic Cardiomyopathy

    Authors: , , , , , - Journal of the American College of Cardiology 2014 cited by 646

  20. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction

    Authors: , , , , , , - Journal of the American College of Cardiology 2020 cited by 178

  21. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States

    Authors: , , , , - The American Journal of Cardiology 2016 cited by 168

  22. Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - JACC Heart Failure 2023 cited by 46

  23. Three-dimensional Deep Convolutional Neural Networks for Automated Myocardial Scar Quantification in Hypertrophic Cardiomyopathy: A Multicenter Multivendor Study

    Authors: , , , , , , - Radiology 2019 cited by 94

  24. Radiomics of Late Gadolinium Enhancement Reveals Prognostic Value of Myocardial Scar Heterogeneity in Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , - JACC. Cardiovascular imaging 2023 cited by 54